Daclizumab in multiple sclerosis.

CONCLUSIONS: Daclizumab has shown efficacy in slowing the inflammatory process of multiple sclerosis, although the appearance of potentially serious side effects has not allowed its use to significantly impact current clinical practice. The development of new drugs in multiple sclerosis must be contingent on maintaining or improving the risk-benefit profile with respect to those already in use. PMID: 29645071 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29645071?dopt=Abstract

Source: Revista de Neurologia - April 14, 2018 Category: Neurology Authors: Perez-Miralles FC Tags: Rev Neurol Source Type: research